The Power of oRNATM Therapeutics

WHAT IS oRNATM CIRCULAR RNA?

Built on groundbreaking research from Prof. Daniel Anderson’s lab at MIT, our oRNATM technology is the next revolution in RNA therapeutics: synthetic circular RNA efficiently generated by an elegant and proprietary molecular platform. oRNATM circular RNAs lack caps and tails and are always full-length, and are made by combining nature-driven insights with rational design. They are easily made, well-tolerated, and are engineered to express therapeutic proteins through original and proprietary mechanisms.

LEARN MORE ABOUT THE FOUNDATIONAL SCIENCE

Two studies by Orna co-founders Dr. Alex Wesselhoeft, Prof. Daniel Anderson, and researchers demonstrate the use of oRNA for robust and stable protein expression in eukaryotic cells and are among the first studies to suggest and show oRNA as a promising alternative to linear mRNA.


KEY ADVANTAGES

This innovative class offers several key advantages over traditional linear mRNA-based approaches.

SIMPLIFIED PRODUCTION – Without caps or tails, our oRNATM technology is produced in a one-step process and are readily purified as obligate, full-length molecules.

SUPERIOR PROTEIN EXPRESSION – Our oRNATM technology exhibits longer functional persistence and improved levels of protein expression in cells compared to linear mRNAs, resulting in substantially higher protein production per dose.

IMPROVED FORMULATABILITY – Our oRNATM technology is inherently more compact in nanoparticle formulations resulting in simplified encapsulation using a variety of lipid nanoparticle (LNP) chemistries.

LIMITLESS POTENTIAL

Just as a ripple spreads out in a pond, our oRNATM platform has a breadth of applications across multiple disease areas including cancer, regenerative medicine, protein replacement, infectious diseases, and autoimmunity. Within these areas, we focus on those where we can make the biggest difference for patients and ourselves.